Intra M, Rotmensz N, Veronesi P, Colleoni M, Iodice S, Paganelli G, et al. Outcomes for women with ductal carcinoma-in situ and a positive sentinel node: a multi-institutional audit. Moore KH, Sweeney KJ, Wilson ME, Goldberg JI, Buchanan CL, Tan LK, et al. The incidence and significance of micrometastases in lymph nodes of patients with ductal carcinoma in situ and T1a carcinoma of the breast. 2008 196:566–8.īroekhuizen LN, Wijsman JH, Peterse JL, Rutgers EJ. Do sentinel node micrometastases predict recurrence risk in ductal carcinoma in situ and ductal carcinoma in situ with microinvasion? Am J Surg. Murphy CD, Jones JL, Javid SH, Michaelson JS, Nolan ME, Lipsitz SR, et al. Prognostic classification of breast ductal carcinoma-in situ. Silverstein MJ, Poller DN, Waisman JR, Colburn WJ, Barth A, Gierson ED, et al. 2005 31:13–8.Ĭonsensus Conference on the classification of ductal carcinoma in situ. The prevalence of non-sentinel node metastases in breast cancer patients with sentinel node micrometastases. Leidenius MH, Vironen JH, Riihela MS, Krogerus LA, Toivonen TS, von Smitten KA, et al. Sentinel node biopsy in breast cancer: five years experience from Denmark. 2004 91:1245–52.Ĭhristiansen P, Friis E, Balslev E, Jensen D, Moller S. Meta-analysis of non-sentinel node metastases associated with micrometastatic sentinel nodes in breast cancer. 2005 241:319–25.Ĭserni G, Gregori D, Merletti F, Sapino A, Mano MP, Ponti A, et al. Predicting the risk for additional axillary metastases in patients with breast carcinoma and positive sentinel lymph node biopsy. Viale G, Maiorano E, Pruneri G, Mastropasqua MG, Valentini S, Galimberti V, et al. Sentinel node biopsy is not sensible in breast cancer patients with large primary tumours. Leidenius MH, Krogerus LA, Toivonen TS, von Smitten KA. Epidemiology of ductal carcinoma in situ. Role of axillary sentinel lymph node biopsy in patients with pure ductal carcinoma in situ of the breast. Zavagno G, Carcoforo P, Marconato R, Franchini Z, Scalco G, Burelli P, et al. Predictors of invasive breast cancer in patients with an initial diagnosis of ductal carcinoma in situ: a guide to selective use of sentinel lymph node biopsy in management of ductal carcinoma in situ. Yen TW, Hunt KK, Ross MI, Mirza NQ, Babiera GV, Meric-Bernstam F, et al. Sentinel lymph node biopsy for localised ductal carcinoma in situ? Breast. Veronesi P, Intra M, Vento AR, Naninato P, Caldarella P, Paganelli G, et al. Sentinel node biopsy in ductal carcinoma in situ patients. Pendas S, Dauway E, Giuliano R, Ku N, Cox CE, Reintgen DS. Core biopsy diagnosis of ductal carcinoma in situ: an indication for sentinel lymph node biopsy. Mittendorf EA, Arciero CA, Gutchell V, Hooke J, Shriver CD. Sentinel lymph node biopsy: is it indicated in patients with high-risk ductal carcinoma-in situ and ductal carcinoma-in situ with microinvasion? Ann Surg Oncol. Klauber-DeMore N, Tan LK, Liberman L, Kaptain S, Fey J, Borgen P, et al. Axillary sentinel lymph node biopsy in patients with pure ductal carcinoma in situ of the breast. Intra M, Veronesi P, Mazzarol G, Galimberti V, Luini A, Sacchini V, et al. Importance of lymphatic mapping in ductal carcinoma in situ (DCIS): why map DCIS? Am Surg. 2000 51:17–32.Ĭox CE, Nguyen K, Gray RJ, Salud C, Ku NN, Dupont E, et al. In light of this study, these findings do not affect the outcome of DCIS or DCISM patients. ConclusionsĭCIS and DCISM patients do have tumor positive findings, but a majority of these are ITC or micrometastases. One patient with pure DCIS and tumor-negative SNB developed overt axillary metastases and later also distant metastases. During a median follow-up of 50 months (range 7–123 months) there were 5 local recurrences. Only 1 of them, a patient with DCISM, had additional tumor positive finding in the ALND. Also, 16 patients, 10 with pure DCIS and 6 with DCISM, underwent completion axillary lymph node dissection (ALND). Of these, 14 were in pure DCIS patients (1 macrometastasis, 1 micrometastasis, 12 ITC) and 7 in DCISM patients (1 macrometastasis, 2 micrometastases, 4 ITC). ResultsĪltogether, 21 patients had tumor-positive sentinel node findings. The median follow-up was 50 months (range 7–123 months). Patient, tumor, SNB procedure, and follow-up data were gathered. MethodsĪ total of 280 breast cancer patients with pure or microinvasive DCIS underwent SNB between April 2001 and December 2010 at the Breast Surgery Unit of Helsinki University Central Hospital. The aim of this study is to examine the outcome of DCIS and DCISM patients with SNB. The prognostic significance of such findings is largely unknown. In sentinel node biopsy (SNB), tumor-positive findings, mainly micrometastases and isolated tumor cells (ITC) have been found in up to 8%–16% of patients with pure ductal carcinoma in situ (DCIS) or microinvasive DCIS (DCISM).
0 Comments
Leave a Reply. |
Details
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |